AI cell therapy development co Somite raises $47m

Cell therapy development company You have It has announced the completion of a $ 47 million series of financing, led by Khosla Ventures, with the participation of Scifi VC, the Chan Zuckerberg, Fusion Fund, Ajinomoto Group Ventures, Pitango Healthtech, Techaviv, Harpoon Ventures, to, to, to Dr. R. Martin Chavez (Openai). The company takes advantage of the basic models and Amnesty International to accelerate the development of human cell therapy,

Somite AI builds Deltasstem, which is the basic platform and model designed to revolutionize human cell production. This financing is placed from physical artificial intelligence to accelerate the main treatment programs, including beta cells of type 1 diabetes, arthritis of bone applications, satellite cells for muscle diseases, blood -forming cells, and developing the Deltastem platform capabilities.

Somite Ai was postponed by Dr. Misha Petron, an Israeli businessman of artificial intelligence who previously sold a choir.

Dr. Peterson said, “We build the foundation model for the human cell. By generating the world’s largest data collection in the world at 1000X the efficiency of current methods, we are training Deltasstem to provide protocols with unparalleled purity and expansion and reliability. We are going quickly towards the moment of Alfafold for developmental biology, while empowering limited production to anyone, to anyone.

Somite AI capsule creates cellular transmission data on an unprecedented scale, achieving a larger 1000x efficiency of existing methodologies. This data is fed into the Deltassem Foundation model, which speeds up and improves the development of new cell distinction protocols.

It was published by Globes, Israel Business News – En.globes.co.il – on May 13, 2025.

© Copy Publish Publisher Itonut (1983) Ltd. , 2025.